Galmed Pharmaceuticals (GLMD) Income Statement (2012 - 2025)
Annual Income Statement report data from Dec 31, 2012 to Dec 31, 2025 for Galmed Pharmaceuticals (GLMD).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||||||
Total Revenue | - | - | - | - | - | - | - | 2.04M (+87.16%) | 1.09M (+131.91%) | 470K | - | - | - | - |
Operating Expenses | ||||||||||||||
Research And Development | 4.87M (+63.42%) | 2.98M (-16.53%) | 3.57M (-72.54%) | 13M (-52.24%) | 27M (+4.37%) | 26M (+43.45%) | 18M (+118.77%) | 8.31M (-13.89%) | 9.65M (-32.38%) | 14M (+87.02%) | 7.63M (+14.56%) | 6.66M (-7.63%) | 7.21M (+195.49%) | 2.44M |
Selling General And Administrative | 3.64M (+10.30%) | 3.30M (-15.82%) | 3.92M (-15.88%) | 4.66M (-17.67%) | 5.66M (+37.05%) | 4.13M (-1.67%) | 4.20M (-5.41%) | 4.44M (+16.84%) | 3.80M (+23.38%) | 3.08M (-5.23%) | 3.25M (+31.05%) | 2.48M (-66.30%) | 7.36M (+966.67%) | 690K |
Operating Expenses | 8.51M (+35.51%) | 6.28M (-16.15%) | 7.49M (-57.56%) | 18M (-46.32%) | 33M (+8.84%) | 30M (+34.99%) | 22M (+108.77%) | 11M (-13.27%) | 12M (-26.78%) | 17M (+55.15%) | 11M (+19.04%) | 9.14M (-37.27%) | 15M (+364.01%) | 3.14M |
Depreciation And Amortization | - | 80K (+166.67%) | 30K (-25.00%) | 40K (0.00%) | 40K (0.00%) | 40K (0.00%) | 40K (-89.74%) | 390K (+62.50%) | 240K (+41.18%) | 170K (+240.00%) | 50K (+400.00%) | 10K | - | 10K |
Operating Income | ||||||||||||||
Operating Income | - | - | - | - | - | -30.21M (+34.99%) | -22.38M (+108.96%) | -10.71M (-13.35%) | -12.36M | - | - | - | - | - |
Ebit | -10.31M (+37.10%) | -7.52M (+8.83%) | -6.91M (-61.33%) | -17.87M (-44.96%) | -32.47M (+7.48%) | -30.21M (+34.99%) | -22.38M (+108.96%) | -10.71M (-13.35%) | -12.36M (-26.65%) | -16.85M (+58.66%) | -10.62M (+16.70%) | -9.10M (-47.94%) | -17.48M (+456.69%) | -3.14M |
EBITDA | -10.31M (+38.76%) | -7.43M (+7.99%) | -6.88M (-61.41%) | -17.83M (-45.00%) | -32.42M (+7.46%) | -30.17M (+35.05%) | -22.34M (+116.26%) | -10.33M (-14.77%) | -12.12M (-27.34%) | -16.68M (+57.81%) | -10.57M (+16.28%) | -9.09M (-48.00%) | -17.48M (+456.69%) | -3.14M |
Other Income / Expenses | ||||||||||||||
Other Non Operating Income | 740K (+42.31%) | 520K (-10.34%) | 580K | -210.00K | 410K (-71.53%) | 1.44M | -1.91M | 930K (+1228.57%) | 70K (+75.00%) | 40K (-84.00%) | 250K (+525.00%) | 40K | -2.91M (+29000.00%) | -10.00K |
Net Income | ||||||||||||||
Income Before Tax | - | 7.52M (+8.83%) | 6.91M (-61.33%) | 18M | -32.47M (+12.86%) | -28.77M (+40.62%) | -20.46M | - | - | - | - | - | - | - |
Income Tax Expense | - | - | - | - | - | - | - | 80K | - | 110K | - | - | - | 10K |
Net Income From Continuing Operations | -10.31M (+37.10%) | -7.52M (+8.83%) | -6.91M (-61.33%) | -17.87M (-44.96%) | -32.47M (+12.86%) | -28.77M (+40.62%) | -20.46M (+107.51%) | -9.86M (-19.84%) | -12.30M (-27.43%) | -16.95M (+59.60%) | -10.62M (+16.70%) | -9.10M (-47.94%) | -17.48M (+454.92%) | -3.15M |
Net Income | -10.31M (+37.10%) | -7.52M (+8.83%) | -6.91M (-61.33%) | -17.87M (-44.96%) | -32.47M (+12.86%) | -28.77M (+40.62%) | -20.46M (+107.51%) | -9.86M (-19.84%) | -12.30M (-27.43%) | -16.95M (+59.60%) | -10.62M (+16.70%) | -9.10M (-47.94%) | -17.48M (+454.92%) | -3.15M |
Comprehensive Income Net Of Tax | -10.20M (+36.36%) | -7.48M (+12.99%) | -6.62M (-64.10%) | -18.44M (-43.97%) | -32.91M (+15.35%) | -28.53M (+39.78%) | -20.41M (+107.00%) | -9.86M (-19.31%) | -12.22M (-27.39%) | -16.83M (+55.40%) | -10.83M (+19.01%) | -9.10M (-47.94%) | -17.48M (+454.92%) | -3.15M |